These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20499825)

  • 21. Diabetes prevention: can insulin secretagogues do the job?
    Westerhaus B; Gosmanov AR; Umpierrez GE
    Prim Care Diabetes; 2011 Jul; 5(2):73-80. PubMed ID: 21185798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nateglinide and mitiglinide].
    Odawara M
    Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [NAVIGATOR trial (nateglinide)].
    Tsujii S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():483-7. PubMed ID: 15779426
    [No Abstract]   [Full Text] [Related]  

  • 26. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.
    Shrikhande G; Khaodhiar L; Scali S; Lima C; Hubbard M; Dudley K; Ganda O; Ferran C; Veves A
    J Vasc Surg; 2006 Apr; 43(4):760-70; discussion 770-1. PubMed ID: 16616233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The significance of generic valsartan in the treatment of patients].
    Vértes A
    Lege Artis Med; 2011 Feb; 21(2):117-21. PubMed ID: 21710709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of valsartan on the incidence of diabetes.
    Luan FL
    N Engl J Med; 2010 Aug; 363(8):792; author reply 792-3. PubMed ID: 20718670
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events.
    Sawada T; Takahashi T; Yamada H; Dahlöf B; Matsubara H;
    J Hum Hypertens; 2009 Mar; 23(3):188-95. PubMed ID: 18800142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE; McInnes GT; Mancia G; Hua TA; Julius S; Weber MA; Coca A; Girerd X; Jamerson K; Larochelle P; Macdonald T; Schmieder RE; Anthony Schork M; Viskoper R; Widimsky J; Zanchetti A
    Blood Press; 2008; 17(3):170-7. PubMed ID: 18608200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
    Whitelaw DC; Clark PM; Smith JM; Nattrass M
    Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
    van der Zijl NJ; Moors CC; Goossens GH; Hermans MM; Blaak EE; Diamant M
    Diabetes Care; 2011 Apr; 34(4):845-51. PubMed ID: 21330640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.
    Yang ZH; Peng XD
    Chin Med J (Engl); 2010 Dec; 123(24):3640-3. PubMed ID: 22166644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.